Ivabradine Viatris

Ivabradine, the active ingredient in Ivabradine Viatris, is an If channel inhibitor presented as a tablet for oral use. It reduces heart rate in patients with chronic stable angina and heart failure with reduced ejection fraction.

GNH USA supplies Ivabradine Viatris as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine acts on the cardiac If current to lower heart rate in specific cardiovascular conditions. - Chronic stable angina: decreases the frequency of angina attacks in patients whose resting heart rate remains above 70 bpm despite optimal therapy. - Heart failure with reduced ejection fraction: improves symptoms and reduces hospitalization risk in patients with left‑ventricular ejection fraction ≤35 % and elevated heart rate. - Elevated resting heart rate: helps achieve target heart rates in patients who remain tachycardic despite beta‑blocker treatment.

Common Side Effects: - Visual disturbances (phosphenes): transient luminous phenomena. - Bradycardia: slower than normal heart rate. - Headache: mild to moderate intensity. - Dizziness or light‑headedness. - Fatigue or general weakness. - Blurred vision.

Serious or Rare Side Effects: - Symptomatic bradycardia requiring medical attention. - Atrial fibrillation or other serious arrhythmias. - Severe hypotension. - Persistent visual disturbances. - Allergic reactions such as rash, pruritus, or angioedema. - Hepatic enzyme elevations.

Ivabradine should be used with careful clinical monitoring. - Heart rate monitoring: ensure resting heart rate remains above the minimum safe threshold. - Severe hypotension: avoid in patients with systolic blood pressure <90 mmHg. - Hepatic impairment: dose adjustment may be required in moderate to severe liver disease. - Concomitant bradycardic agents: use caution when combined with beta‑blockers, digoxin, or calcium‑channel blockers. - Sick sinus syndrome or atrioventricular block: contraindicated. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Ivabradine may interact with several medicines that affect heart rate or its metabolism. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels. - Other bradycardic agents (beta‑blockers, digoxin, non‑dihydropyridine calcium‑channel blockers): risk of excessive heart‑rate reduction. - Concomitant use with other If channel inhibitors: additive effect on heart rate.

Moderate Interactions (Monitor Closely):\n- Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may modestly raise ivabradine exposure. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Antihypertensive drugs: monitor blood pressure and heart rate for additive effects.